Resolution source:

https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2024

From Wikipedia:

Vertex announced in January 2024 that VX-548 successfully met several enpoints in its Phase III trials. The drug relieved moderate to severe post-surgical pain. Vertex hopes the drug, which operates on peripheral nerves, will avoid the addictive potential of opioids. There are many other small molecule sodium channel blocker candidates.

Independence:

I will not take positions related to this question on any market sites.